Moreover O
, O
dichlorodiphenyldich B
( O
p B
, I
p I
' I
- I
DDE I
) O
was O
found O
in O
all O
placentas O
. O

The O
data O
indicates O
that O
fetal O
exposure O
to O
dioxins B
and O
furans B
( O
PCDD B
/ O
Fs O
) O
, O
polychlorinated B
biphenyls I
( O
PCBs B
) O
, O
p B
, I
p I
' I
- I
DDE I
, O
and O
methylmercury B
depends O
on O
the O
mother O
' O
s O
parity O
, O
and O
age O
. O

The O
structures O
were O
elucidated O
based O
on O
( B
13 I
) I
C I
- O
and O
( B
1 I
) I
H I
- O
NMR O
as O
well O
as O
2D O
- O
NMR O
, O
IR O
and O
different O
MS O
spectra O
and O
the O
immunomodulation O
activity O
for O
compound O
1 O
was O
evaluated O
through O
lymphocyte O
proliferation O
assay O
, O
IL O
- O
2 O
assay O
, O
oxidative O
burst O
of O
phagocytic O
leukocytes O
and O
through O
their O
cytotoxicity O
on O
two O
cell O
lines O
. O

In O
this O
study O
, O
we O
fabricated O
microneedles O
from O
a O
biocompatible O
polymer O
, O
namely O
, O
poly B
( I
ethylene I
glycol I
) I
diacrylate I
. O

In O
the O
medium O
polar O
fraction O
, O
we O
isolated O
the O
two O
hydroxy B
- I
phenyl I
- I
ethyl I
alcohols I
( O
hydroxyl B
- I
tyrosol I
and O
tyrosol B
) O
that O
are O
the O
main O
component O
of O
olives O
. O

Combined O
potential O
energy O
mapping O
and O
RRKM O
calculations O
of O
dissociation O
rate O
constants O
identified O
N B
- I
C I
( I
alpha I
) I
bond O
cleavages O
as O
the O
most O
favorable O
dissociation O
pathways O
, O
in O
a O
stark O
contrast O
to O
the O
experimental O
results O
. O

Chalcones B
( O
1 B
, I
3 I
- I
Diphenyl I
- I
2 I
- I
propen I
- I
1 I
- I
one I
) O
are O
constituted O
by O
a O
three O
carbon B
alpha B
, I
beta I
- I
unsaturated I
carbonyl I
system O
. O

Silent O
information O
regulator O
2 O
( O
Sir2 O
) O
enzymes O
or O
sirtuins O
are O
a O
family O
of O
evolutionarily O
conserved O
intracellular O
protein O
deacetylases O
that O
can O
catalyze O
the O
acetyl B
group O
removal O
from O
the O
specific O
N B
epsilon I
- I
acetyl I
- I
lysine I
( O
AcK O
) O
side O
chains O
on O
a O
variety O
of O
proteins O
from O
all O
kingdoms O
of O
life O
. O

Specifically O
, O
the O
sirtuin O
- O
catalyzed O
AcK O
side O
chain O
deacetylation O
is O
not O
merely O
an O
amide B
hydrolysis O
reaction O
, O
instead O
is O
coupled O
to O
the O
nicotinamide B
cleavage O
from O
beta B
- I
nicotinamide I
adenine I
dinucleotide I
( O
beta B
- I
NAD I
+ O
or O
NAD B
+ O
) O
with O
the O
generation O
of O
three O
enzymatic O
products O
, O
i O
. O
e O
. O
the O
deacetylated O
protein O
species O
, O
nicotinamide O
, O
and O
2 B
' I
- I
O I
- I
acetyl I
- I
ADP I
- I
ribose I
( O
2 B
' I
- I
O I
- I
AADPR I
) O
. O

We O
synthesized O
18 O
alloferon B
analogues O
: O
12 O
peptides O
with O
sequences O
shortened O
from O
N B
- O
or O
C B
- O
terminus O
and O
6 O
N B
- O
terminally O
modified O
analogues O
H O
- O
X O
( O
1 O
) O
- O
Gly B
- I
Val I
- I
Ser I
- I
Gly I
- I
His I
- I
Gly I
- I
Gln I
- I
His I
- I
Gly I
- I
Val I
- I
His I
- I
Gly I
- I
OH I
, O
where O
X O
( O
1 O
) O
= O
Phe B
( O
13 O
) O
, O
Tyr B
( O
14 O
) O
, O
Trp B
( O
15 O
) O
, O
Phg O
( O
16 O
) O
, O
Phe B
( I
p I
- I
Cl I
) I
( O
17 O
) O
, O
and O
Phe B
( I
p I
- I
OMe I
) I
( O
18 O
) O

We O
synthesized O
18 O
alloferon B
analogues O
: O
12 O
peptides O
with O
sequences O
shortened O
from O
N B
- O
or O
C B
- O
terminus O
and O
6 O
N B
- O
terminally O
modified O
analogues O
H O
- O
X O
( O
1 O
) O
- O
Gly B
- I
Val I
- I
Ser I
- I
Gly I
- I
His I
- I
Gly I
- I
Gln I
- I
His I
- I
Gly I
- I
Val I
- I
His I
- I
Gly I
- I
OH I
, O
where O
X O
( O
1 O
) O
= O
Phe B
( O
13 O
) O
, O
Tyr B
( O
14 O
) O
, O
Trp B
( O
15 O
) O
, O
Phg O
( O
16 O
) O
, O
Phe B
( I
p I
- I
Cl I
) I
( O
17 O
) O
, O
and O
Phe B
( I
p I
- I
OMe I
) I
( O
18 O
) O

The O
role O
of O
long O
chain O
omega B
- I
3 I
polyunsaturated I
fatty I
acids I
in O
reducing O
lipid O
peroxidation O
among O
elderly O
patients O
with O
mild O
cognitive O
impairment O
: O
a O
case O
- O
control O
study O
. O

The O
present O
work O
explores O
the O
effect O
of O
dietary O
omega B
- I
3 I
polyunsaturated I
fatty I
acids I
( O
PUFAs B
) O
intake O
on O
lipid O
peroxidation O
among O
mild O
cognitive O
impairment O
( O
MCI O
) O
patients O
. O

3 I
- I
bis I
( I
4 I
- I
hydroxyphenyl I
) I
- I
4 I
- I
methyl I
- I
5 I
- I
[ I
4 I
- I
( I
2 I
- I
piperidinylethoxy I
) I
phenol I
] O
- O
1H B
- I
pyrazole I
dihydrochloride I
] O
or O
a O
selective O
ER O
beta O
antagonist O
- O
PHTPP B
( O
4 B
- I
[ I
2 I
- I
phenyl I
- I
5 I
, I
7 I
- I
bis I
( I
trifluoromethyl I
) I
pyrazolo I
[ I
1 I
, I
5 I
- I
a I
] I
pyrimidin I
- I
3 I
- I
yl I
] I
phenol I
) O
. O

Di B
2 I
- I
ethyl I
hexyl I
phthalate I
affects O
differentiation O
and O
matrix O
mineralization O
of O
rat O
calvarial O
osteoblasts O
- O
- O
in O
vitro O
. O

Several O
studies O
suggest O
that O
dietary O
phosphate B
, O
serum O
phosphate B
and O
1 B
, I
25 I
- I
dihydroxyvitamin I
D I
[ O
1 B
, I
25 I
( I
OH I
) I
( I
2 I
) I
D I
] O
are O
candidate O
regulators O
of O
FGF O
- O
23 O
. O

The O
production O
of O
reactive O
oxygen B
species O
( O
ROS O
) O
and O
changes O
in O
mitochondrial O
membrane O
potential O
( O
Delta O
Psi O
m O
) O
in O
cells O
exposed O
to O
Epo B
A I
, O
Epo B
B I
and O
PTX B
were O
studied O
using O
specific O
fluorescence O
probes O
, O
DCFH B
( I
2 I
) I
- I
DA I
( O
2 B
' I
, I
7 I
' I
- I
dichlorodihydrofluor I
diacetate I
) O
and O
JC B
- I
1 I
( O
5 B
, I
5 I
' I
, I
6 I
, I
6 I
' I
- I
tetrachloro I
- I
1 I
, I
1 I
' I
, I
3 I
, I
3 I
' I
- I
tetraethylbenzimidaz I
) O
. O

Direct O
- O
acting O
CB1 O
agonists O
, O
including O
Delta B
( I
9 I
) I
- I
tetrahydrocannabinol I
, O
WIN B
55 I
, I
212 I
[ O
R B
- I
( I
1 I
) I
- I
[ I
2 I
, I
3 I
- I
dihydro I
- I
5 I
- I
methyl I
- I
3 I
- I
[ I
( I
morpholinyl I
) I
methyl I
] I
pyrrolo I
[ I
1 I
, I
2 I
, I
3 I
- I
de I
] I
- I
1 I
, I
4 I
- I
benzoxazinyl I
] I
- I
( I
1 I
- I
naphthalenyl I
) I
methanone I
mesylate I
] O
, O
AM2389 B
[ O
9 B
beta I
- I
hydroxy I
- I
3 I
- I
( I
1 I
- I
hexyl I

As O
a O
proof O
of O
concept O
, O
we O
employed O
a O
Protein O
Kinase O
A O
( O
PKA O
) O
- O
dependent O
switch O
and O
coupled O
it O
to O
a O
lipid O
phosphatase O
to O
manipulate O
the O
level O
of O
phosphatidylinositol B
4 I
, I
5 I
- I
bisphosphate I
( O
PI B
( I
4 I
, I
5 I
) I
P I
( I
2 I
) I
) O
in O
living O
cells O
. O

In O
this O
article O
, O
we O
checked O
the O
effect O
of O
2 B
, I
3 I
- I
dimercaptosuccinic I
acid I
- O
coated O
Fe B
( I
3 I
) I
O I
( I
4 I
) I
nanoparticles O
on O
gene O
expression O
of O
mouse O
macrophage O
RAW264 O
. O
7 O
cells O
and O
found O
that O
the O
transcription O
of O
several O
important O
genes O
related O
to O
intracellular O
iron B
homeostasis O
were O
significantly O
changed O
. O

We O
demonstrate O
that O
the O
energy O
bandgap O
of O
layered O
, O
high O
- O
dielectric O
alpha B
- I
MoO I
( I
3 I
) I
can O
be O
reduced O
to O
values O
viable O
for O
the O
fabrication O
of O
2D O
electronic O
devices O
. O

As O
a O
result O
, O
devices O
with O
alpha B
- I
MoO I
( I
3 I
) I
of O
~ O
11 O
nm O
thickness O
and O
carrier O
mobilities O
larger O
than O
1100 O
cm O
( O
2 O
) O
V O
( O
- O
1 O
) O
s O
( O
- O
1 O
) O
are O
obtained O
. O

LPV B
( O
50 O
micro O
M O
) O
, O
RTV B
( O
5 O
micro O
M O
) O
, O
and O
LPV B
/ O
r O
( O
5 O
and O
50 O
micro O
M O
/ O
5 O
micro O
M O
) O
significantly O
decreased O
the O
accumulation O
of O
total O
measured O
endogenous O
bile B
acids I
( O
TCA B
, O
glycocholic B
acid I
, O
taurochenodeoxycholi B
acid I
, O
glycochenodeoxycholi B
acid I
, O
and O
alpha B
/ I
beta I
- I
tauromuricholic I
acid I
) O
in O
SCRH O
. O

Delta B
( I
9 I
) I
- I
tetrahydrocannabinol I
( O
Delta B
( I
9 I
) I
- I
THC I
) O
has O
potent O
immune O
modulatory O
properties O
and O
can O
impair O
pathogen O
- O
induced O
immune O
defenses O
, O
which O
in O
part O
have O
been O
attributed O
to O
ligation O
of O
the O
cannabinoid O
receptors O
1 O
( O
CB O
( O
1 O
) O
) O
and O
2 O
( O
CB O
( O
2 O
) O
) O
. O

Delta B
( I
9 I
) I
- I
tetrahydrocannabinol I
( O
Delta B
( I
9 I
) I
- I
THC I
) O
has O
potent O
immune O
modulatory O
properties O
and O
can O
impair O
pathogen O
- O
induced O
immune O
defenses O
, O
which O
in O
part O
have O
been O
attributed O
to O
ligation O
of O
the O
cannabinoid O
receptors O
1 O
( O
CB O
( O
1 O
) O
) O
and O
2 O
( O
CB O
( O
2 O
) O
) O
. O

This O
study O
focused O
on O
the O
modulation O
of O
the O
inflammatory O
immune O
response O
to O
influenza O
by O
Delta B
( I
9 I
) I
- I
THC I
and O
the O
role O
of O
CB O
( O
1 O
) O
and O
/ O
or O
CB O
( O
2 O
) O
as O
receptor O
targets O
for O
Delta B
( I
9 I
) I
- I
THC I
. O

This O
study O
focused O
on O
the O
modulation O
of O
the O
inflammatory O
immune O
response O
to O
influenza O
by O
Delta B
( I
9 I
) I
- I
THC I
and O
the O
role O
of O
CB O
( O
1 O
) O
and O
/ O
or O
CB O
( O
2 O
) O
as O
receptor O
targets O
for O
Delta B
( I
9 I
) I
- I
THC I
. O

C57Bl O
/ O
6 O
( O
wild O
type O
) O
and O
CB O
( O
1 O
) O
( O
- O
/ O
- O
) O
CB O
( O
2 O
) O
( O
- O
/ O
- O
) O
mice O
were O
administered O
Delta B
( I
9 I
) I
- I
THC I
( O
75 O
mg O
/ O
kg O
) O
surrounding O
the O
intranasal O
instillation O
of O
A O
/ O
PR O
/ O
8 O
/ O
34 O
influenza O
virus O
. O

Three O
days O
post O
infection O
( O
dpi O
) O
, O
Delta B
( I
9 I
) I
- I
THC I
broadly O
decreased O
expression O
levels O
of O
mRNA O
induced O
by O
the O
innate O
immune O
response O
to O
influenza O
, O
suppressed O
the O
percentage O
of O
interferon O
- O
gamma O
( O
IFN O
- O
gamma O
) O
- O
producing O
CD4 O
( O
+ O
) O
and O
interleukin O
- O
17 O
- O
producing O
NK1 O
. O
1 O
( O
+ O
) O
cells O
, O
and O
reduced O
the O
influx O
of O
antigen O
- O
presenting O
cells O
( O
APC O
) O
, O
including O
inflammatory O
myeloid O
cells O
and O
monocytes O
/ O
macrophages O
, O
into O
the O
lung O
in O
a O
CB O
( O
1 O
) O
- O
and O
/ O
or O
CB O
( O
2 O
) O
- O
dependent O
manner O
. O

Delta B
( I
9 I
) I
- I
THC I
had O
little O
effect O
on O
the O
expression O
of O
CD86 O
, O
major O
histocompatibility O
complex O
I O
( O
MHC O
I O
) O
, O
and O
MHC O
II O
by O
APC O
isolated O
from O
the O
lung O
. O

In O
vitro O
studies O
demonstrated O
that O
lipopolysaccharide O
( O
LPS O
) O
- O
induced O
maturation O
was O
suppressed O
by O
Delta B
( I
9 I
) I
- I
THC I
in O
bone O
marrow O
- O
derived O
DC O
( O
bmDC O
) O
. O

Furthermore O
, O
antigen O
- O
specific O
IFN O
- O
gamma O
production O
by O
CD8 O
( O
+ O
) O
T O
cells O
after O
coculture O
was O
reduced O
by O
Delta B
( I
9 I
) I
- I
THC I
treatment O
of O
bmDC O
in O
a O
CB O
( O
1 O
) O
- O
and O
/ O
or O
CB O
( O
2 O
) O
- O
dependent O
manner O
. O

Collectively O
, O
these O
studies O
suggest O
that O
Delta B
( I
9 I
) I
- I
THC I
potently O
suppresses O
myeloid O
cell O
immune O
function O
, O
in O
a O
manner O
involving O
CB O
( O
1 O
) O
and O
/ O
or O
CB O
( O
2 O
) O
, O
thereby O
impairing O
immune O
responses O
to O
influenza O
infection O
. O

The O
aldehyde B
dehydrogenase O
( O
ALDH O
) O
superfamily O
is O
composed O
of O
nicotinamide B
adenine I
dinucleotide I
( I
phosphate I
) I
( O
NAD B
( I
P I
) I
( I
+ I
) I
) O
- O
dependent O
enzymes O
that O
catalyze O
the O
oxidation O
of O
aldehydes B
to O
their O
corresponding O
carboxylic B
acids I
. O

Fabrication O
of O
3 O
- O
dimensional O
cellular O
constructs O
via O
microstereolithograp O
using O
a O
simple O
, O
three O
- O
component O
, O
poly B
( I
ethylene I
glycol I
) I
acrylate I
- O
based O
system O
. O

For O
example O
, O
8 B
, I
8 I
- I
diethyldihydroberber I
chloride I
( O
5b O
) O
exhibited O
in O
vitro O
IC50 O
values O
of O
77 O
, O
100 O
, O
and O
5 O
. O
3 O
nM O
against O
these O
three O
parasites O
, O
respectively O
. O

While O
the O
natural O
product O
berberine O
is O
a O
weak O
DNA O
binder O
, O
the O
8 B
, I
8 I
- I
DDBs I
displayed O
no O
affinity O
for O
DNA O
, O
as O
assessed O
by O
changes O
in O
the O
melting O
temperature O
of O
poly B
( I
dA I
. I
dT I
) I
DNA O
. O

Selected O
8 B
, I
8 I
- I
DDBs I
showed O
efficacy O
in O
mouse O
models O
of O
visceral O
leishmaniasis O
and O
African O
trypanosomiasis O
, O
with O
8 B
, I
8 I
- I
dimethyldihydroberbe I
chloride I
( O
5a O
) O
reducing O
liver O
parasitemia O
by O
46 O
% O
in O
L O
. O
donovani O
- O
infected O
BALB O
/ O
c O
mice O
when O
given O
at O
an O
intraperitoneal O
dose O
of O
10 O
mg O
/ O
kg O
/ O
day O
for O
five O
days O
. O

Approximately O
81 O
. O
6 O
% O
of O
the O
dose O
was O
recovered O
in O
urine O
, O
mainly O
as O
NBP B
- I
11 I
- I
oic I
acid I
( O
M5 O
- O
2 O
) O
and O
glucuronide O
conjugates O
of O
M5 O
- O
2 O
and O
mono O
- O
hydroxylated O
products O
. O

Formation O
of O
M5 O
- O
2 O
was O
much O
faster O
than O
that O
of O
M2 O
, O
and O
M5 O
- O
2 O
can O
undergo O
beta O
- O
oxidation O
to O
yield O
phthalide B
- I
3 I
- I
acetic I
acid I
in O
rat O
liver O
homogenate O
. O

In O
the O
present O
report O
15 O
day O
- O
old O
rats O
were O
injected O
with O
0 O
. O
3 O
mu O
mol O
of O
diphenyl B
ditelluride I
( B
PhTe I
) I
( I
2 I
) I
/ O
kg O
body O
weight O
and O
parameters O
of O
neurodegeneration O
were O
analyzed O
in O
slices O
from O
cerebellum O
3 O
and O
6 O
days O
afterwards O
. O

Also O
, O
reactive O
astrogliosis O
takes O
part O
of O
the O
early O
responses O
to O
the O
insult O
with O
( B
PhTe I
) I
( I
2 I
) I
, O
evidenced O
by O
upregulated O
GFAP O
in O
Western O
blot O
, O
PCR O
and O
immunofluorescence O
analysis O
. O

Six O
days O
after O
( B
PhTe I
) I
( I
2 I
) I
injection O
we O
found O
persistent O
astrogliosis O
, O
increased O
propidium B
iodide I
( O
PI O
) O
positive O
cells O
in O
NeuN O
positive O
population O
evidenced O
by O
flow O
cytometry O
and O
reduced O
immunofluorescence O
for O
NeuN O
, O
suggesting O
that O
the O
in O
vivo O
exposure O
to O
( B
PhTe I
) I
( I
2 I
) I
progressed O
to O
neuronal O
death O
. O

Six O
days O
after O
( B
PhTe I
) I
( I
2 I
) I
injection O
we O
found O
persistent O
astrogliosis O
, O
increased O
propidium B
iodide I
( O
PI O
) O
positive O
cells O
in O
NeuN O
positive O
population O
evidenced O
by O
flow O
cytometry O
and O
reduced O
immunofluorescence O
for O
NeuN O
, O
suggesting O
that O
the O
in O
vivo O
exposure O
to O
( B
PhTe I
) I
( I
2 I
) I
progressed O
to O
neuronal O
death O
. O

Neurodegeneration O
was O
related O
with O
decreased O
[ B
( I
3 I
) I
H I
] I
glutamate I
uptake O
and O
decreased O
Akt O
immunoreactivity O
, O
however O
phospho O
- O
GSK O
- O
3 O
- O
beta O
( O
Ser9 B
) O
was O
not O
altered O
in O
( B
PhTe I
) I
( I
2 I
) I
injected O
rat O
. O

Therefore O
, O
the O
present O
results O
show O
that O
the O
earlier O
cerebellar O
responses O
to O
( B
PhTe I
) I
( I
2 I
) I
include O
disruption O
of O
cytoskeletal O
homeostasis O
that O
could O
be O
related O
with O
MAPK O
and O
PKA O
activation O
and O
reactive O
astrogliosis O
. O

The O
progression O
of O
these O
responses O
are O
therefore O
likely O
to O
be O
critical O
for O
the O
outcome O
of O
the O
neurodegeneration O
provoked O
by O
( B
PhTe I
) I
( I
2 I
) I
in O
rat O
cerebellum O
. O

It O
was O
shown O
that O
PEG2000 B
- I
Tyr I
( I
6 I
) I
undergoes O
thermoresponsive O
hydrogelation O
at O
a O
low O
concentration O
range O
of O
0 O
. O
25 O
- O
3 O
. O
0 O
wt O
% O
within O
a O
temperature O
range O
of O
25 O
- O
50 O
degrees O
C O
. O

Synthesis O
and O
antiplasmodial O
evaluation O
of O
novel O
( B
4 I
- I
aminobutyloxy I
) I
quinolines I
. O

, I
3 I
- I
dihydro I
- I
5 I
- I
methyl I
- I
3 I
- I
[ I
( I
morpholinyl I
) I
methyl I
] I
pyrrolo I
[ I
1 I
, I
2 I
, I
3 I
- I
de I
] I
- I
1 I
, I
4 I
- I
benzoxazinyl I
] I
- I
( I
1 I
- I
naphthalenyl I
) I
methanone I
mesylate I
( O
WIN55 B
, I
212 I
. I
2 I
) O
, O
Delta B
( I
9 I
) I
- I
tetrahydrocannabinol I
( O
Delta B
( I
9 I
) I
- I
THC I
) O
, O
( B
R I
) I
- I
( I
+ I
) I
- I
arachidonyl I
- I
1 I
' I
- I
hydroxy I
- I
2 I
' I
- I

, I
3 I
- I
dihydro I
- I
5 I
- I
methyl I
- I
3 I
- I
[ I
( I
morpholinyl I
) I
methyl I
] I
pyrrolo I
[ I
1 I
, I
2 I
, I
3 I
- I
de I
] I
- I
1 I
, I
4 I
- I
benzoxazinyl I
] I
- I
( I
1 I
- I
naphthalenyl I
) I
methanone I
mesylate I
( O
WIN55 B
, I
212 I
. I
2 I
) O
, O
Delta B
( I
9 I
) I
- I
tetrahydrocannabinol I
( O
Delta B
( I
9 I
) I
- I
THC I
) O
, O
( B
R I
) I
- I
( I
+ I
) I
- I
arachidonyl I
- I
1 I
' I
- I
hydroxy I
- I
2 I
' I
- I

Dose O
- O
response O
re O
- O
determinations O
during O
chronic O
treatment O
revealed O
the O
following O
: O
1 O
) O
> O
250 O
- O
fold O
( O
AM411 B
, O
methanandamide B
) O
and O
> O
45 O
- O
fold O
( O
AM4054 B
, O
WIN55 B
, I
212 I
. I
2 I
, O
Delta B
( I
9 I
) I
- I
THC I
) O
rightward O
shifts O
in O
the O
ED O
( O
50 O
) O
values O
for O
CB O
( O
1 O
) O
agonists O
; O
2 O
) O
> O
100 O
- O
fold O
and O
> O
20 O
- O
fold O
leftward O
shifts O
in O
the O
ED O
( O
50 O
) O
values O
for O
SR141716A B
and O
AM4113 B
, O
respectively O
; O
and O
3 O
) O
approximately O
4 O
. O
8 O
- O
fold O
and O
10 O
- O

Antimutagenic O
evaluation O
of O
vitamins B
B1 I
, I
B6 I
and I
B12 I
in O
vitro O
and O
in O
vivo O
, O
with O
the O
Ames O
test O
. O

Much O
work O
has O
been O
focused O
on O
aprotic O
Li B
- I
O I
( I
2 I
) I
cells O
( O
mostly O
with O
carbonate B
- O
based O
electrolytes O
and O
Li B
( I
2 I
) I
O I
( I
2 I
) I
as O
a O
potential O
discharge O
product O
) O
, O
where O
large O
overpotentials O
are O
observed O
and O
a O
complex O
cell O
chemistry O
is O
found O
. O

In O
fact O
, O
recent O
studies O
evidence O
that O
Li B
- I
O I
( I
2 I
) I
cells O
suffer O
from O
irreversible O
electrolyte O
decomposition O
during O
cycling O
. O

Here O
we O
report O
on O
a O
Na B
- I
O I
( I
2 I
) I
cell O
reversibly O
discharging O
/ O
charging O
at O
very O
low O
overpotentials O
( O
< O
200 O
mV O
) O
and O
current O
densities O
as O
high O
as O
0 O
. O
2 O
mA O
cm O
( O
- O
2 O
) O
using O
a O
pure O
carbon B
cathode O
without O
an O
added O
catalyst O
. O

Synthesis O
, O
characterization O
and O
pharmacodynamics O
of O
vitamin B
- I
B I
( I
12 I
) I
- O
conjugated O
glucagon O
- O
like O
peptide O
- O
1 O
. O

Enantiospecific O
total O
synthesis O
of O
( B
- I
) I
- I
bengamide I
E I
. O

The O
high O
- O
efficacy O
agonist O
R B
( I
- I
) I
- I
norpropylapomorphine I
[ O
( B
- I
) I
- I
NPA I
] O
, O
low O
- O
efficacy O
agonist O
aripiprazole B
( O
ARI B
) O
, O
and O
antagonist O
eticlopride B
( O
ETIC B
) O
were O
administered O
acutely O
to O
monkeys O
self O
- O
administering O
cocaine B
under O
a O
food O
- O
cocaine B
choice O
procedure O
in O
which O
a O
cocaine B
self O
- O
administration O
dose O
- O
effect O
curve O
was O
determined O
daily O
. O

Previous O
studies O
have O
shown O
inexplicable O
declines O
in O
breeding O
waterbirds O
within O
western O
New O
York O
/ O
New O
Jersey O
Harbor O
between O
1996 O
and O
2002 O
and O
elevated O
polychlorinated B
dibenzo I
- I
p I
- I
dioxins I
and O
polychlorinated B
biphenyls I
( O
PCBs B
) O
in O
double O
- O
crested O
cormorant O
( O
Phalacrocorax O
auritus O
) O
eggs O
. O

CBMs O
that O
bind O
beta O
- O
glucan O
chains O
often O
display O
broad O
specificity O
recognizing O
beta O
1 O
, O
4 O
- O
glucans O
( O
cellulose O
) O
, O
beta O
1 O
, O
3 O
- O
beta O
1 O
, O
4 O
- O
mixed O
linked O
glucans O
and O
xyloglucan O
, O
a O
beta O
1 O
, O
4 O
- O
glucan O
decorated O
with O
alpha B
1 I
, I
6 I
- I
xylose I
residues O
, O
by O
targeting O
structures O
common O
to O
the O
three O
polysaccharides O
. O

In O
addition O
, O
the O
fluorescence O
wavelength O
of O
the O
bis B
( I
p I
- I
nitrophenyl I
) I
derivative O
is O
remarkably O
solvent O
- O
dependent O
in O
a O
manner O
that O
correlates O
with O
the O
solvent O
polarity O
parameter O
E O
( O
T O
) O
( O
30 O
) O
. O

Vibrational O
absorption O
( O
VA O
) O
and O
vibrational O
circular O
dichroism O
( O
VCD O
) O
spectra O
of O
methyl B
mandelate I
, O
a O
prototype O
chiral O
molecule O
, O
in O
a O
series O
of O
organic O
solvents O
, O
namely O
methanol B
( O
MeOH B
- I
d I
( I
4 I
) I
) O
, O
dimethyl B
sulfoxide I
( O
DMSO B
- I
d I
( I
6 I
) I
) O
, O
and O
chloroform B
( O
CDCl B
( I
3 I
) I
) O
, O
have O
been O
measured O
in O
the O
finger O
print O
region O
from O
1800 O
to O
1150 O
cm O
( O
- O
1 O
) O
. O

Vibrational O
absorption O
( O
VA O
) O
and O
vibrational O
circular O
dichroism O
( O
VCD O
) O
spectra O
of O
methyl B
mandelate I
, O
a O
prototype O
chiral O
molecule O
, O
in O
a O
series O
of O
organic O
solvents O
, O
namely O
methanol B
( O
MeOH B
- I
d I
( I
4 I
) I
) O
, O
dimethyl B
sulfoxide I
( O
DMSO B
- I
d I
( I
6 I
) I
) O
, O
and O
chloroform B
( O
CDCl B
( I
3 I
) I
) O
, O
have O
been O
measured O
in O
the O
finger O
print O
region O
from O
1800 O
to O
1150 O
cm O
( O
- O
1 O
) O
. O

We O
begin O
by O
capturing O
RISC O
using O
a O
complementary O
2 B
' I
- I
O I
- I
methyl I
oligonucleotide O
tethered O
to O
beads O
. O

Effect O
of O
guanidinylation O
on O
the O
properties O
of O
poly B
( I
2 I
- I
aminoethylmethacryla I
) I
- O
based O
antibacterial O
materials O
. O

Subsequently O
the O
methods O
were O
applied O
for O
the O
identification O
and O
quantification O
of O
chlorogenic B
acid I
( O
5 B
- I
CQA I
) O
and O
1 B
, I
5 I
- I
dicaffeoylquinic I
acid I
( O
1 B
, I
5 I
- I
DCQA I
) O
as O
main O
compounds O
in O
samples O
. O

In O
addition O
, O
Neu2000 B
effectively O
scavenged O
hydroxyl B
radicals O
generated O
by O
iron B
( I
III I
) I
- I
ascorbate I
, O
reduced O
protein O
carbonyl B
formation O
mediated O
by O
hydroxyl B
radicals O
and O
peroxynitrite B
, O
and O
prevented O
glutathione B
oxidation O
caused O
by O
tert B
- I
butyl I
hydroperoxide I
in O
isolated O
mitochondria O
. O

Mag1 O
excises O
N3 B
- I
and I
N7 I
- I
alkylguanines I
and O
1 B
, I
N I
( I
6 I
) I
- I
ethenoadenine I
from O
DNA O
, O
whereas O
Mag2 O
has O
been O
reported O
to O
have O
no O
detectible O
alkylpurine B
base O
excision O
activity O
despite O
high O
sequence O
and O
active O
site O
similarity O
to O
Mag1 O
. O

Survey O
of O
recent O
literature O
related O
to O
the O
biologically O
active O
4 B
( I
3H I
) I
- I
quinazolinones I
containing O
fused O
heterocycles O
. O

Drugs O
under O
investigation O
can O
be O
broadly O
subdivided O
into O
four O
groups O
: O
( O
1 O
) O
Agents O
that O
create O
DNA O
damage O
( O
i O
. O
e O
. O
cisplatin B
, O
cyclophosphamide B
) O
; O
( O
2 O
) O
Agents O
that O
inhibit O
poly B
( I
ADP I
- I
ribose I
) I
polymerase O
( O
PARP O
) O
; O
( O
3 O
) O
Tyrosin B
- O
kinase O
inhibitors O
and O
monoclonal O
antibodies O
; O
( O
4 O
) O
Agents O
that O
inhibit O
downstream O
signals O
. O

In O
this O
paper O
, O
the O
fabrication O
, O
characterization O
, O
and O
application O
in O
oxygen B
sensing O
are O
reported O
for O
a O
novel O
multifunctional O
nanomaterial O
of O
[ O
Ru B
( I
bpy I
) I
( I
2 I
) I
phen I
- O
MMS O
] O
( O
bpy B
, O
2 B
, I
2 I
' I
- I
bipyridyl I
; O
phen B
, O
phenathrolin B
) O
which O
was O
simply O
prepared O
by O
covalently O
grafting O
the O
ruthenium B
( I
II I
) I
polypyridyl I
compounds O
into O
the O
channels O
of O
magnetic O
mesoporous O
silica B
nanocomposites O
( O
MMS O
) O
. O

Differential O
anti O
- O
ischemic O
efficacy O
and O
therapeutic O
time O
window O
of O
trans B
- I
and I
cis I
- I
hinokiresinols I
: O
Stereo O
- O
specific O
antioxidant O
and O
anti O
- O
inflammatory O
activities O
. O

In O
the O
present O
study O
, O
we O
investigated O
anti O
- O
ischemic O
effects O
of O
trans B
- I
and I
cis I
- I
hinokiresinols I
using O
in O
vitro O
as O
well O
as O
in O
vivo O
experimental O
models O
. O

Mechanistic O
studies O
reveal O
that O
the O
NOGEL O
is O
dependent O
upon O
repair O
of O
O B
( I
6 I
) I
- I
methylguanine I
( O
O B
( I
6 I
) I
MeG I
) O
by O
the O
suicide O
enzyme O
O B
( I
6 I
) I
MeG I
- O
DNA O
methyltransferase O
( O
MGMT O
) O
. O

The O
results O
indicated O
that O
SKF83959 B
dramatically O
promoted O
the O
binding O
of O
( B
3 I
) I
H I
( I
+ I
) I
- I
pentazocine I
( O
a O
selective O
sigma O
- O
1 O
receptor O
agonist O
) O
to O
the O
sigma O
- O
1 O
receptor O
in O
brain O
and O
liver O
tissues O
but O
produced O
no O
effect O
on O
( B
3 I
) I
H I
- I
progesterone I
binding O
( O
a O
sigma O
- O
1 O
receptor O
antagonist O
) O
. O

Moreover O
, O
all O
three O
tested O
chemicals O
elicited O
no O
significant O
effect O
on O
( B
3 I
) I
H I
- I
1 I
, I
3 I
- I
di I
( I
2 I
- I
tolyl I
) I
- I
guanidine I
( O
( B
3 I
) I
H I
- I
DTG I
) O
binding O
to O
the O
sigma O
- O
2 O
receptor O
. O

Biodegradable O
and O
amphiphilic O
block O
copolymers O
based O
on O
poly B
( I
epsilon I
- I
caprolactone I
) I
( O
PCL B
= O
B O
) O
and O
poly B
( I
ethylene I
oxide I
) I
( O
PEO B
= O
A O
) O
, O
with O
AB O
and O
ABA O
architectures O
, O
were O
assembled O
in O
" O
core O
- O
shell O
" O
NPs O
and O
loaded O
with O
both O
DTX B
and O
ZnPc B
employing O
the O
melting O
/ O
sonication O
method O
. O

The O
intrinsic O
clearance O
for O
R B
- I
and I
S I
- I
EDDP I
formation O
from O
racemic B
methadone I
was O
diminished O
approximately O
6 O
- O
fold O
and O
3 O
- O
fold O
for O
R B
- I
and I
S I
- I
methadone I
, O
respectively O
. O

The O
intrinsic O
clearance O
for O
R B
- I
and I
S I
- I
EDDP I
formation O
from O
racemic B
methadone I
was O
diminished O
approximately O
6 O
- O
fold O
and O
3 O
- O
fold O
for O
R B
- I
and I
S I
- I
methadone I
, O
respectively O
. O

O B
( I
6 I
) I
- I
Alkylguanine I
- O
DNA O
alkyltransferase O
( O
AGT O
) O
is O
a O
DNA O
repair O
protein O
which O
removes O
alkyl O
groups O
from O
the O
O O
- O
6 O
position O
of O
guanine B
, O
thereby O
providing O
strong O
resistance O
to O
anticancer O
agents O
which O
alkylate O
this O
position O
. O

Aphagrandinoid B
A I
( O
1 O
) O
, O
a O
29 B
- I
nor I
- I
cycloart I
triterpenoid I
, O
features O
with O
a O
sprio O
ring O
system O
at O
the O
side O
chain O
, O
while O
aphagrandinoid B
C I
( O
3 O
) O
is O
a O
pentnortriterpenoid B
. O

However O
, O
other O
steroids B
, O
including O
Delta B
( I
5 I
) I
- I
androstenediol I
, O
5 B
alpha I
- I
androstanediol I
and O
27 B
- I
hydroxycholesterol I
, O
which O
have O
a O
saturated O
A O
ring O
containing O
a O
3 B
beta I
- I
hydroxyl I
and O
a O
C19 O
methyl B
group O
, O
also O
mediate O
physiological O
responses O
through O
binding O
to O
estrogen B
receptor O
- O
alpha O
( O
ER O
alpha O
) O
and O
ER O
beta O
. O

Asymmetric O
synthesis O
and O
anti O
- O
protozoal O
activity O
of O
the O
8 B
, I
4 I
' I
- I
oxyneolignans I
virolin B
, O
surinamensin B
and O
analogues O
. O

The O
asymmetric O
synthesis O
of O
8 B
, I
4 I
' I
- I
oxyneolignans I
( B
- I
) I
- I
virolin I
, O
( B
- I
) I
- I
surinamensin I
and O
a O
number O
of O
analogues O
has O
been O
achieved O
. O

Phthalazinone B
inhibitors O
of O
inosine B
- I
5 I
' I
- I
monophosphate I
dehydrogenase O
from O
Cryptosporidium O
parvum O
. O

Reactive O
oxygen B
species O
( O
ROS O
) O
were O
detected O
by O
2 B
, I
7 I
- I
dichlorofluorescin I
diacetate I
fluorophotometry O
. O

However O
, O
recent O
clinical O
studies O
have O
shown O
that O
a O
single O
low O
- O
dose O
injection O
of O
ketamine B
, O
an O
N B
- I
methyl I
d I
- I
aspartate I
receptor O
( O
NMDAR O
) O
antagonist O
, O
has O
rapid O
antidepressant O
effects O
that O
are O
observed O
within O
hours O
and O
are O
long O
lasting O
. O

The O
increase O
in O
ROS O
formation O
and O
cell O
death O
was O
assayed O
using O
the O
fluorescent O
probe O
2 B
, I
7 I
- I
dichlorofluorescin I
diacetate I
( O
DCFH B
- I
DA I
) O
and O
the O
trypan B
blue I
exclusion O
assay O
. O

The O
two O
- O
electron O
reduction O
of O
O B
( I
2 I
) I
by O
1 B
, I
1 I
' I
- I
dibromoferrocene I
( O
Br B
( I
2 I
) I
Fc I
) O
was O
catalyzed O
by O
Co B
( I
II I
) I
( I
Ch I
) I
, O
whereas O
virtually O
no O
reduction O
of O
O B
( I
2 I
) I
occurred O
with O
Co B
( I
II I
) I
( I
OEP I
) I
. O

Binary O
diffusion O
coefficients O
for O
mixtures O
of O
ionic O
liquids O
[ B
EMIM I
] I
[ I
N I
( I
CN I
) I
2 I
] I
, O
[ B
EMIM I
] I
[ I
NTf2 I
] I
, O
and O
[ B
HMIM I
] I
[ I
NTf2 I
] I
with O
acetone B
and O
ethanol B
by O
dynamic O
light O
scattering O
( O
DLS O
) O
. O

Binary O
diffusion O
coefficients O
for O
mixtures O
of O
ionic O
liquids O
[ B
EMIM I
] I
[ I
N I
( I
CN I
) I
2 I
] I
, O
[ B
EMIM I
] I
[ I
NTf2 I
] I
, O
and O
[ B
HMIM I
] I
[ I
NTf2 I
] I
with O
acetone B
and O
ethanol B
by O
dynamic O
light O
scattering O
( O
DLS O
) O
. O

Mutual O
diffusivities O
for O
binary O
mixtures O
of O
the O
ionic O
liquids O
( O
ILs O
) O
[ B
EMIM I
] I
[ I
N I
( I
CN I
) I
2 I
] I
( O
1 B
- I
ethyl I
- I
3 I
- I
methylimidazolium I
dicyanimide I
) O
, O
[ B
EMIM I
] I
[ I
NTf2 I
] I
( O
1 B
- I
ethyl I
- I
3 I
- I
methylimidazolium I
bis I
( I
trifluoromethylsulfo I
) I
imide I
) O
, O
and O
[ B
HMIM I
] I
[ I
NTf2 I
] I
( O
1 B
- I
hexyl I
- I
3 I
- I
methylimidazolium I
bis I
( I

Mutual O
diffusivities O
for O
binary O
mixtures O
of O
the O
ionic O
liquids O
( O
ILs O
) O
[ B
EMIM I
] I
[ I
N I
( I
CN I
) I
2 I
] I
( O
1 B
- I
ethyl I
- I
3 I
- I
methylimidazolium I
dicyanimide I
) O
, O
[ B
EMIM I
] I
[ I
NTf2 I
] I
( O
1 B
- I
ethyl I
- I
3 I
- I
methylimidazolium I
bis I
( I
trifluoromethylsulfo I
) I
imide I
) O
, O
and O
[ B
HMIM I
] I
[ I
NTf2 I
] I
( O
1 B
- I
hexyl I
- I
3 I
- I
methylimidazolium I
bis I
( I

For O
the O
mixtures O
of O
[ B
EMIM I
] I
[ I
NTf2 I
] I
with O
ethanol B
, O
however O
, O
a O
minimum O
of O
the O
mutual O
diffusivities O
was O
found O
in O
the O
ethanol B
mole O
fraction O
range O
from O
0 O
. O
7 O
to O
0 O
. O
8 O
, O
which O
may O
hint O
at O
the O
vicinity O
of O
a O
critical O
demixing O
point O
. O

Poly B
( I
4 I
- I
hydroxybutyrate I
) I
( O
P4HB B
) O
is O
a O
highly O
elastic O
polymer O
, O
whereas O
poly B
( I
3 I
- I
hydroxypropionate I
) I
( O
P3HP B
) O
is O
a O
polymer O
with O
enormous O
tensile O
strength O
. O

Poly B
( I
4 I
- I
hydroxybutyrate I
) I
( O
P4HB B
) O
is O
a O
highly O
elastic O
polymer O
, O
whereas O
poly B
( I
3 I
- I
hydroxypropionate I
) I
( O
P3HP B
) O
is O
a O
polymer O
with O
enormous O
tensile O
strength O
. O

The O
secondary O
metabolites O
lapachol O
, O
alpha B
- I
and I
beta I
- I
lapachone I
and O
a O
series O
of O
25 O
related O
synthetic O
1 B
, I
4 I
- I
naphthoquinones I
were O
screened O
against O
the O
oesophageal O
cancer O
cell O
line O
( O
WHCO1 O
) O
. O

1 B
, I
10 I
- I
phenanthroline I
and O
2 B
, I
2 I
' I
- I
bipy I
= O
2 B
, I
2 I
' I
- I
bipyridine I
) O
were O
synthesized O
. O

1 B
, I
10 I
- I
phenanthroline I
and O
2 B
, I
2 I
' I
- I
bipy I
= O
2 B
, I
2 I
' I
- I
bipyridine I
) O
were O
synthesized O
. O

The O
structure O
activity O
relationship O
( O
SAR O
) O
revealed O
that O
the O
position O
and O
physicochemical O
character O
of O
the O
aromatic O
substituent O
proved O
to O
be O
critical O
for O
the O
levels O
of O
3 B
, I
4 I
- I
dihydroxyphenylaceti I
acid I
( O
DOPAC B
) O
in O
the O
brain O
of O
freely O
moving O
rats O
. O

Four O
new O
lanostane B
triterpenes I
, O
butyl B
lucidenate I
P I
( O
1 O
) O
, O
butyl B
lucidenate I
D I
( I
2 I
) I
( O
2 O
) O
, O
butyl B
lucidenate I
E I
( I
2 I
) I
( O
3 O
) O
and O
butyl B
lucidenate I
Q I
( O
4 O
) O
along O
with O
11 O
known O
compounds O
( O
5 O
- O
15 O
) O
were O
isolated O
from O
the O
fruiting O
bodies O
of O
Ganoderma O
lucidum O
. O

Four O
new O
lanostane B
triterpenes I
, O
butyl B
lucidenate I
P I
( O
1 O
) O
, O
butyl B
lucidenate I
D I
( I
2 I
) I
( O
2 O
) O
, O
butyl B
lucidenate I
E I
( I
2 I
) I
( O
3 O
) O
and O
butyl B
lucidenate I
Q I
( O
4 O
) O
along O
with O
11 O
known O
compounds O
( O
5 O
- O
15 O
) O
were O
isolated O
from O
the O
fruiting O
bodies O
of O
Ganoderma O
lucidum O
. O

The O
dot O
orientations O
are O
[ O
11 O
[ O
overline O
] O
0 O
] O
( O
Si B
) O
( O
or O
[ O
1 O
[ O
overline O
] O
10 O
] O
( O
Si B
) O
) O
/ O
/ O
[ O
112 O
[ O
overline O
] O
0 O
] O
( O
AlN B
) O
and O
( B
111 I
) I
( I
Si I
) I
/ O
/ O
( O
0001 O
) O
( O
AlN B
) O
, O
which O
are O
similar O
( O
or O
identical O
) O
to O
the O
orientation O
of O
AlN B
relative O
to O
the O
Si B
substrate O
. O

Ticlopidine B
also O
significantly O
increased O
the O
dose O
- O
adjusted O
plasma O
area O
under O
the O
curve O
for O
R B
- I
and I
S I
- I
methadone I
by O
20 O
% O
and O
60 O
% O
, O
respectively O
, O
after O
both O
intravenous O
and O
oral O
dosing O
. O

The O
analogs O
bearing O
endo B
- I
azabicyclic I
amines I
and I
alcohols I
( O
7 O
, O
8 O
, O
11 O
, O
and O
12 O
) O
exhibited O
full O
agonistic O
activities O
while O
the O
analogs O
with O
exo B
- I
azabicyclic I
amines I
and I
alcohols I
were O
proved O
as O
partial O
agonists O
( O
9 O
, O
10 O
, O
13 O
, O
and O
14 O
) O
regardless O
of O
their O
EC O
( O
50 O
) O
values O
. O

The O
analogs O
bearing O
endo B
- I
azabicyclic I
amines I
and I
alcohols I
( O
7 O
, O
8 O
, O
11 O
, O
and O
12 O
) O
exhibited O
full O
agonistic O
activities O
while O
the O
analogs O
with O
exo B
- I
azabicyclic I
amines I
and I
alcohols I
were O
proved O
as O
partial O
agonists O
( O
9 O
, O
10 O
, O
13 O
, O
and O
14 O
) O
regardless O
of O
their O
EC O
( O
50 O
) O
values O
. O

The O
alpha O
- O
subunit O
of O
tryptophan B
synthase O
( O
alpha O
TS O
) O
catalyzes O
the O
conversion O
of O
indole B
- I
3 I
- I
glycerol I
phosphate I
to O
d B
- I
glyceraldehyde I
- I
3 I
- I
phosphate I
and O
indole B
. O

3 B
, I
3 I
' I
- I
Diindolymethane I
ameliorates O
adriamycin B
- O
induced O
cardiac O
fibrosis O
via O
activation O
of O
a O
BRCA1 O
- O
dependent O
anti O
- O
oxidant O
pathway O
. O

In O
the O
present O
study O
, O
we O
demonstrate O
that O
3 B
, I
3 I
' I
- I
diindolymethane I
( O
DIM B
) O
exhibits O
a O
significant O
anti O
- O
fibrosis O
effect O
on O
cardiac O
tissue O
in O
an O
animal O
model O
of O
adriamycin B
- O
induced O
cardiac O
fibrosis O
( O
AICF O
) O
. O

Structural O
Modifications O
to O
Tetrahydropyridine B
- I
3 I
- I
carboxylate I
Esters I
en O
Route O
to O
the O
Discovery O
of O
M O
( O
5 O
) O
- O
Preferring O
Muscarinic O
Receptor O
Orthosteric O
Antagonists O
. O

Gut O
microbiota O
regulates O
bile B
acid I
metabolism O
by O
reducing O
the O
levels O
of O
tauro B
- I
beta I
- I
muricholic I
acid I
, O
a O
naturally O
occurring O
FXR O
antagonist O
. O

To O
identify O
the O
molecular O
mechanisms O
underlying O
this O
effect O
, O
we O
used O
an O
adoptive O
transfer O
approach O
in O
which O
dendritic O
cells O
( O
DCs O
) O
from O
the O
draining O
lymph O
nodes O
of O
donor O
mice O
that O
had O
been O
UVB O
- O
exposed O
and O
sensitized O
to O
2 B
, I
4 I
, I
- I
dinitrofluorobenzene I
( O
DNFB B
) O
were O
transferred O
into O
na O
i O
ve O
recipient O
mice O
. O

Utilizing O
tin B
( I
II I
) I
bis I
( I
2 I
- I
ethylhexanoate I
) I
, O
aluminum B
salan I
, O
and O
aluminum B
salen I
catalysts O
, O
the O
copolymers O
were O
synthesized O
through O
the O
ring O
- O
opening O
polymerization O
of O
d O
- O
, O
l O
- O
, O
rac O
- O
, O
or O
a O
blend O
of O
l B
- I
and I
rac I
- I
lactide I
using O
monomethoxy B
- I
poly I
( I
ethylene I
glycol I
) I
as O
a O
macroinitiator O
. O

Two O
ruthenium B
( I
ii I
) I
polypyridyl I
complexes O
[ B
Ru I
( I
phen I
) I
2 I
( I
4idip I
) I
] I
( I
ClO4 I
) I
2 I
( O
) O
and O
[ B
Ru I
( I
bpy I
) I
2 I
( I
4idip I
) I
] I
( I
ClO4 I
) I
2 I
( O
) O
( O
phen B
= O
1 B
, I
10 I
- I
phenanthroline I
, O
bpy B
= O
2 B
, I
2 I
' I
- I
bipyridine I
, O
4idip B
= O
4 B
- I
indoleimidazo I
[ I
4 I
, I
5 I
- I
f I
] I
[ I
1 I
, I
10 I
] I
phenanthroline I
) O
designed O
as O
telomeric O

Injectable O
superparamagnets O
: O
highly O
elastic O
and O
degradable O
poly B
( I
N I
- I
isopropylacrylamide I
) I
- O
superparamagnetic O
iron B
oxide I
nanoparticle O
( O
SPION O
) O
composite O
hydrogels O
. O

Injectable O
, O
in O
situ O
- O
gelling O
magnetic O
composite O
materials O
have O
been O
fabricated O
by O
using O
aldehyde B
- O
functionalized O
dextran O
to O
cross O
- O
link O
superparamagnetic O
nanoparticles O
surface O
- O
functionalized O
with O
hydrazide B
- O
functionalized O
poly B
( I
N I
- I
isopropylacrylamide I
) I
( O
pNIPAM B
) O
. O

Saturated B
fatty I
acids I
( O
FA O
) O
were O
grafted O
using O
tyrosine B
as O
a O
spacer O
group O
to O
the O
cyclotriphosphazene B
ring O
along O
with O
equimolar O
hydrophilic O
methoxy B
poly I
( I
ethylene I
glycol I
) I
( O
MPEG B
) O
in O
cis O
- O
nongeminal O
way O
. O

The O
performance O
of O
MCR O
- O
ALS O
was O
studied O
in O
the O
modeling O
of O
non O
- O
linear O
kinetic O
- O
spectrophotometric O
data O
acquired O
by O
a O
stopped O
- O
flow O
system O
for O
the O
quantitation O
of O
tartrazine B
in O
the O
presence O
of O
brilliant B
blue I
and I
sunset I
yellow I
FCF I
as O
possible O
interferents O
. O

Influence O
of O
the O
bifunctional O
chelator O
on O
the O
pharmacokinetic O
properties O
of O
99mTc B
( I
CO I
) I
3 I
- O
labeled O
cyclic B
alpha I
- I
melanocyte I
stimulating I
hormone I
analog O
. O

Most O
notable O
is O
a O
Bi B
- I
Ag I
- I
Cu I
oxide I
( O
Bi B
: O
Ag B
: O
Cu B
atomic O
ratio O
of O
22 O
: O
3 O
: O
11 O
) O
which O
shows O
4 O
times O
higher O
photocurrent O
than O
CuBi2O4 B
. O

Two O
new O
phenolic B
glycosides I
, O
linamarin B
gallate I
( O
1 O
) O
and O
walsuraside B
B I
( O
2 O
) O
, O
together O
with O
nine O
known O
compounds O
, O
catechin B
( O
3 O
) O
, O
epicatechin B
( O
4 O
) O
, O
epicatechin B
3 I
- I
O I
- I
gallate I
( O
5 O
) O
, O
epicatechin B
3 I
- I
O I
- I
( I
3 I
- I
O I
- I
methyl I
) I
gallate I
( O
6 O
) O
, O
epicatechin B
3 I
- I
O I
- I
( I
3 I
, I
5 I
- I
O I
- I
dimethyl I
) I
gallate I
( O
7 O
) O
, O
epicatechin B
3 I
- I
O I
- I
( I
3 I
, I
4 I
, I
5 I
- I
O I
- I
trimethyl I

Herein O
we O
report O
the O
crystallographic O
structures O
of O
a O
series O
of O
structurally O
related O
metastable O
Mn B
( I
III I
) I
- I
OOR I
compounds O
, O
and O
examine O
their O
spectroscopic O
and O
reactivity O
properties O
. O

The O
four O
reported O
Mn B
( I
III I
) I
- I
OOR I
compounds O
extend O
the O
number O
of O
known O
end O
- O
on O
Mn B
( I
III I
) I
- I
( I
eta I
( I
1 I
) I
- I
peroxos I
) I
to O
six O
. O

Strong O
correlations O
between O
structural O
( O
O B
- I
O I
and O
Mn B
. O
. O
. O
N B
( I
py I
, I
quin I
) I
distances O
) O
, O
spectroscopic O
( O
E O
( O
pi O
v O
* O
( O
O B
- I
O I
) O
- O
- O
> O
Mn B
CT O
band O
) O
, O
nu O
( O
O B
- I
O I
) O
) O
, O
and O
kinetic O
( O
Delta O
H O
( O
+ O
+ O
) O
and O
Delta O
S O
( O
+ O
+ O
) O
) O
parameters O
for O
these O
complexes O
provide O
compelling O
evidence O
for O
rate O
- O
limiting O
O B
- I
O I
bond O
cleavage O
. O

Products O
identified O
in O
the O
final O
reaction O
mixtures O
of O
Mn B
( I
III I
) I
- I
OOR I
decay O
are O
consistent O
with O
homolytic O
O B
- I
O I
bond O
scission O
. O

Cellulose O
microspheres O
bearing O
poly B
( I
epsilon I
- I
caprolactone I
) I
grafts O
of O
different O
molecular O
weights O
were O
investigated O
to O
evaluate O
the O
effect O
of O
graft O
length O
on O
the O
interfacial O
properties O
. O

Omega B
- I
3 I
polyunsaturated I
fatty I
acids I
( O
PUFAs B
) O
are O
known O
to O
alleviate O
joint O
stiffness O
and O
pain O
in O
rheumatoid O
arthritis O
patients O
. O

Changes O
in O
morphometry O
and O
association O
between O
whole O
- O
body O
fatty B
acids I
and O
steroid B
hormone O
profiles O
in O
relation O
to O
bioaccumulation O
patterns O
in O
salmon O
larvae O
exposed O
to O
perfluorooctane B
sulfonic I
or I
perfluorooctane I
carboxylic I
acids I
. O

The O
known O
compounds O
were O
characterised O
as O
n B
- I
tetracosane I
, O
beta B
- I
sitosteryl I
stearate I
, O
eicosanoic B
acid I
, O
stigmasterol B
, O
beta B
- I
sitosterol I
, O
racemosol B
, O
octacosyl B
ferulate I
, O
de B
- I
O I
- I
methyl I
racemosol I
, O
lupeol B
and O
1 B
, I
7 I
, I
8 I
, I
12b I
- I
tetrahydro I
- I
2 I
, I
2 I
, I
4 I
- I
trimethyl I
- I
2H I
- I
benzo I
[ I
6 I
, I
7 I
] I
cyclohepta I
[ I
1 I
, I
2 I
, I
3 I
- I
de I
] I
[ I
1 I
] I

However O
, O
the O
overwhelming O
majority O
of O
previously O
reported O
temperature O
- O
responsive O
polymers O
are O
based O
on O
poly B
( I
N I
- I
isopropylacrylamide I
) I
( O
PNIPAM B
) O
, O
despite O
the O
fact O
that O
a O
wide O
range O
of O
other O
thermoresponsive O
polymers O
have O
demonstrated O
similar O
promise O
for O
the O
preparation O
of O
adaptive O
materials O
. O

Two O
new O
cyclic B
polyamine I
disulfides I
, O
based O
on O
hexa B
- I
and I
octa I
- I
amine I
inserts O
, O
were O
prepared O
and O
their O
transfection O
efficacies O
and O
cytotoxicities O
compared O
with O
our O
previously O
reported O
cyclic B
tri I
- I
and I
tetra I
- I
amine I
disulfides I
. O

The O
second O
series O
of O
compounds O
, O
beta B
- I
lactam I
amino I
acid I
amides I
( O
including O
10k O
and O
11l O
) O
displayed O
potent O
antiproliferative O
activity O
in O
MCF O
- O
7 O
cells O
, O
disrupted O
microtubules O
in O
MCF O
- O
7 O
cells O
and O
also O
inhibited O
the O
polymerisation O
of O
tubulin O
in O
vitro O
. O

Molecular O
modelling O
studies O
indicated O
potential O
binding O
conformations O
for O
the O
beta B
- I
lactam I
amino I
acid I
amides I
10k O
and O
11l O
in O
the O
colchicine B
- O
binding O
site O
of O
tubulin O
. O

In O
most O
cases O
, O
this O
defect O
can O
be O
overcome O
by O
treatment O
with O
all B
- I
trans I
- I
retinoic I
acid I
( O
ATRA B
) O
, O
leading O
to O
complete O
clinical O
remission O
. O

Crotonaldehyde B
, O
a O
highly O
toxic O
alpha B
, I
beta I
- I
unsaturated I
aldehyde I
, O
is O
a O
major O
component O
of O
cigarette O
smoke O
and O
a O
ubiquitous O
environmental O
pollutant O
. O

Furthermore O
mitochondria O
membrane O
potential O
and O
adenosine B
- I
5 I
' I
- I
triphosphate I
( O
ATP B
) O
production O
are O
decreased O
for O
culture O
with O
ZnO B
- O
np O
. O

Chemical O
investigation O
of O
n B
- I
butanol I
fraction O
afforded O
alpha B
- I
amyrin I
3 I
- I
O I
- I
glucopyranoside I
( O
1 O
) O
, O
patuletin B
7 I
- I
O I
- I
glucopyranoside I
( O
2 O
) O
, O
myricitrin B
( O
3 O
) O
and O
a O
new O
oleanane B
triterpene I
saponin I
derivative O
( O
4 O
) O
, O
sophradiol B
3 I
- I
O I
- I
alpha I
- I
L I
- I
( I
1 I
) I
C4 I
- I
rhamnopyranosyl I
- I
( I
1 I
' I
' I
' I
- I
- I
> I
4 I
' I
' I
) I
- I
O I
- I
beta I
- I
D I
- I
( I
4 I
) I
C1 I
- I
galactopyranosyl I

Synthesis O
of O
decacationic B
[ I
60 I
] I
fullerene I
decaiodides I
giving O
photoinduced O
production O
of O
superoxide B
radicals O
and O
effective O
PDT O
- O
mediation O
on O
antimicrobial O
photoinactivation O
. O

We O
used O
the O
well O
- O
characterized O
malonato B
[ I
60 I
] I
fullerene I
diester I
monoadduct O
C60 B
[ I
> I
M I
( I
t I
- I
Bu I
) I
2 I
] I
as O
the O
starting O
fullerene B
derivative O
to O
provide O
a O
better O
synthetic O
route O
to O
C60 B
[ I
> I
M I
( I
C3N6 I
( I
+ I
) I
C3 I
) I
2 I
] I
via O
transesterification O
reaction O
under O
trifluoroacetic B
acid I
catalyzed O
conditions O
. O

Using O
this O
device O
we O
determine O
Km O
and O
kcat O
for O
beta O
- O
galactosidase O
and O
the O
fluorogenic O
substrate O
Resorufin B
beta I
- I
d I
- I
galactopyranoside I
( O
RBG B
) O
to O
be O
442 O
mu O
M O
and O
1070 O
s O
( O
- O
1 O
) O
, O
respectively O
. O

Sulfide B
enhanced O
the O
cleavage O
of O
caspase O
- O
3 O
and O
poly B
( I
ADP I
- I
ribose I
) I
polymerase O
and O
induced O
early O
cellular O
apoptosis O
. O

The O
approach O
is O
designed O
on O
the O
basis O
of O
the O
key O
regioselective O
Diels O
- O
Alder O
reaction O
of O
the O
properly O
substituted O
exo B
- I
2 I
- I
oxazolidinone I
diene I
3 O
with O
acrolein B
( O
4 O
) O
to O
give O
the O
corresponding O
adduct O
2 O
. O

211726 O
, O
and O
respectively O
identified O
as O
25 B
- I
malonyl I
demalonylazalomycin I
F5a I
monoester I
( O
1 O
) O
, O
23 B
- I
valine I
demalonylazalomycin I
F5a I
ester I
( O
2 O
) O
, O
23 B
- I
( I
6 I
- I
methyl I
) I
heptanoic I
acid I
demalonylazalomycins I
F3a I
ester I
( O
3 O
) O
, O
F4a B
ester I
( O
4 O
) O
and O
F5a B
ester I
( O
5 O
) O
, O
23 B
- I
( I
9 I
- I
methyl I
) I
decanoic I
acid I
demalonylazalomycin I
F4a I
ester I
( O
6 O
) O

211726 O
, O
and O
respectively O
identified O
as O
25 B
- I
malonyl I
demalonylazalomycin I
F5a I
monoester I
( O
1 O
) O
, O
23 B
- I
valine I
demalonylazalomycin I
F5a I
ester I
( O
2 O
) O
, O
23 B
- I
( I
6 I
- I
methyl I
) I
heptanoic I
acid I
demalonylazalomycins I
F3a I
ester I
( O
3 O
) O
, O
F4a B
ester I
( O
4 O
) O
and O
F5a B
ester I
( O
5 O
) O
, O
23 B
- I
( I
9 I
- I
methyl I
) I
decanoic I
acid I
demalonylazalomycin I
F4a I
ester I
( O
6 O
) O

Their O
structures O
were O
established O
by O
their O
spectroscopic O
data O
and O
by O
comparing O
with O
those O
of O
azalomycins B
F3a I
, I
F4a I
and I
F5a I
. O

Synthesis O
, O
crystal O
structure O
and O
biological O
evaluation O
of O
a O
main O
group O
seven O
- O
coordinated O
bismuth B
( I
III I
) I
complex O
with O
2 B
- I
acetylpyridine I
N4 I
- I
phenylthiosemicarbaz I
. O

GTLE O
reduces O
AlCl3 B
neurotoxicity O
probably O
via O
antioxidative O
effects O
and O
improves O
mitochondrial O
and O
cholinergic O
synaptic O
functions O
through O
the O
actions O
of O
( B
- I
) I
- I
epigallocatechin I
gallate I
and O
( B
- I
) I
- I
epicatechin I
, O
compounds O
most O
abundantly O
found O
in O
GTLE O
. O

Ureido O
- O
derivatized O
polymers O
, O
such O
as O
poly B
( I
allylurea I
) I
( O
PU O
) O
and O
poly B
( I
L I
- I
citrulline I
) I
derivatives O
, O
exhibited O
upper O
critical O
solution O
temperature O
( O
UCST O
) O
behavior O
under O
physiological O
buffer O
conditions O
as O
we O
previously O
reported O
. O

Here O
we O
describe O
the O
LC O
- O
MS O
/ O
MS O
procedure O
enabling O
simultaneous O
determination O
of O
four O
regioisomers O
( O
8 B
- I
iso I
prostaglandin I
F2 I
alpha I
, O
8 B
- I
iso I
- I
15 I
( I
R I
) I
- I
prostaglandin I
F2 I
alpha I
, O
11 B
beta I
- I
prostaglandin I
F2 I
alpha I
, O
15 B
( I
R I
) I
- I
prostaglandin I
F2 I
alpha I
) O
in O
plasma O
samples O
collected O
from O
mice O
. O

Here O
we O
describe O
the O
LC O
- O
MS O
/ O
MS O
procedure O
enabling O
simultaneous O
determination O
of O
four O
regioisomers O
( O
8 B
- I
iso I
prostaglandin I
F2 I
alpha I
, O
8 B
- I
iso I
- I
15 I
( I
R I
) I
- I
prostaglandin I
F2 I
alpha I
, O
11 B
beta I
- I
prostaglandin I
F2 I
alpha I
, O
15 B
( I
R I
) I
- I
prostaglandin I
F2 I
alpha I
) O
in O
plasma O
samples O
collected O
from O
mice O
. O

Compared O
to O
the O
control O
group O
of O
mice O
, O
both O
oxidative O
stress O
inducers O
tested O
increased O
the O
levels O
of O
three O
out O
of O
four O
isoprostanes O
in O
exposed O
animals O
; O
11 B
beta I
- I
prostaglandin I
F2 I
alpha I
being O
the O
exception O
. O

DOX B
- I
omega I
- I
3 I
FA I
group O
was O
given O
as O
omega B
- I
3 I
FAs I
at O
the O
dose O
of O
400 O
mg O
/ O
kg O
daily O
by O
intragastric O
gavage O
for O
30 O
days O
and O
received O
DOX B
at O
the O
dose O
of O
30 O
mg O
/ O
kg O
intraperitoneally O
on O
day O
28 O
. O

The O
design O
, O
modeling O
, O
synthesis O
and O
biological O
activity O
evaluation O
of O
two O
hybrid O
agents O
formed O
by O
7 B
- I
oxyiminomethylcampto I
derivatives O
and O
diaminedichloro B
- I
platinum I
( I
II I
) I
complex O
are O
reported O
. O

The O
results O
support O
the O
interpretation O
that O
the O
diaminedichloro B
- I
platinum I
( I
II I
) I
complex O
conjugated O
via O
an O
oxyiminomethyl B
linker O
at O
the O
7 O
- O
position O
of O
the O
camptothecin B
resulted O
in O
a O
new O
class O
of O
effective O
antitumor O
compounds O
. O

From O
the O
cytoprotective O
compounds O
eleven O
proved O
to O
possess O
antioxidant O
activity O
( O
ABTS B
radical O
scavenger O
effect O
) O
and O
two O
were O
found O
to O
inhibit O
poly B
( I
ADP I
- I
ribosyl I
) I
ation O
( O
PARylation O
) O
, O
a O
cytotoxic O
pathway O
operating O
in O
severely O
injured O
cells O
. O

In O
conclusion O
we O
identified O
DBM B
analogs O
as O
a O
novel O
class O
of O
cytoprotective O
compounds O
inhibiting O
ERK1 O
/ O
2 O
kinase O
and O
protecting O
from O
necrotic O
cell O
death O
by O
a O
mechanism O
independent O
of O
poly B
( I
ADP I
- I
ribose I
) I
polymerase O
inhibition O
. O

Treatment O
with O
gefitinib B
induced O
mitochondrial O
dysfunction O
, O
cytochrome O
c O
release O
, O
caspase O
- O
3 O
activation O
and O
poly B
( I
ADP I
- I
ribose I
) I
polymerase O
protein O
cleavage O
, O
indicating O
that O
apoptosis O
occurred O
in O
these O
cancer O
cells O
. O

The O
objective O
of O
this O
study O
was O
to O
prepare O
and O
evaluate O
in O
situ O
forming O
gel O
systems O
designed O
by O
combination O
of O
two O
poloxamers B
( I
P407 I
and I
P188 I
) I
and O
hydroxypropylmethylc O
( O
HPMC O
) O
for O
prolonged O
release O
of O
heparin O
. O

The O
hydrolytic O
degradation O
starts O
with O
hydrolysis O
of O
the O
cross O
- O
linker O
, O
N B
, I
O I
- I
dimethacryloyl I
hydroxylamine I
, O
which O
was O
synthesized O
in O
house O
. O

The O
superoxide B
dismutase O
( O
SOD O
) O
activity O
and O
malondialdehyde B
( O
MDA B
) O
level O
in O
cell O
supernatant O
were O
detected O
by O
kits O
while O
the O
intracellular O
reactive O
oxygen B
species O
( O
ROS O
) O
generation O
was O
determined O
by O
2 B
, I
7 I
- I
dichlorodihydrofluor I
diacetate I
( O
DCFH B
- I
DA I
) O
kit O
. O

We O
tested O
associations O
of O
circulating O
vitamin B
D I
metabolite O
concentrations O
with O
subclinical O
atherosclerosis O
among O
1 O
, O
193 O
participants O
with O
type O
1 O
diabetes O
in O
the O
DCCT O
/ O
EDIC O
study O
. O
RESEARCH O
DESIGN O
AND O
METHODSWe O
measured O
plasma O
concentrations O
of O
25 B
- I
hydroxyvitamin I
D I
[ O
25 B
( I
OH I
) I
D I
] O
, O
1 B
, I
25 I
- I
dihydroxyvitamin I
D I
, O
and O
24 B
, I
25 I
- I
dihydroxyvitamin I
D I
by O
mass O
spectrometry O
at O
the O
end O
of O
the O
DCCT O
. O

We O
tested O
associations O
of O
circulating O
vitamin B
D I
metabolite O
concentrations O
with O
subclinical O
atherosclerosis O
among O
1 O
, O
193 O
participants O
with O
type O
1 O
diabetes O
in O
the O
DCCT O
/ O
EDIC O
study O
. O
RESEARCH O
DESIGN O
AND O
METHODSWe O
measured O
plasma O
concentrations O
of O
25 B
- I
hydroxyvitamin I
D I
[ O
25 B
( I
OH I
) I
D I
] O
, O
1 B
, I
25 I
- I
dihydroxyvitamin I
D I
, O
and O
24 B
, I
25 I
- I
dihydroxyvitamin I
D I
by O
mass O
spectrometry O
at O
the O
end O
of O
the O
DCCT O
. O

In O
Vivo O
Degradation O
and O
Elimination O
of O
Injectable O
Ricinoleic B
Acid I
- O
Based O
Poly B
( I
ester I
- I
anhydride I
) I
. O

This O
study O
describes O
the O
use O
of O
the O
pyrrolidinium B
nitrate I
( O
[ B
Pyrr I
] I
[ I
NO3 I
] I
) O
protic O
ionic O
liquid O
( O
PIL O
) O
in O
a O
mixture O
with O
gamma B
butyrolactone I
( O
gamma B
- I
BL I
) O
as O
an O
electrolyte O
for O
carbon B
- O
based O
supercapacitors O
with O
an O
operating O
voltage O
of O
2 O
. O
0 O
V O
and O
at O
very O
low O
temperature O
. O

Regioselective O
mono O
- O
deprotection O
of O
di B
- I
tert I
- I
butylsilylene I
acetal I
was O
critical O
in O
their O
synthesis O
. O

It O
has O
been O
hypothesized O
that O
oils O
containing O
high O
levels O
of O
omega B
- I
3 I
polyunsaturated I
fatty I
acids I
, O
such O
as O
canola O
and O
fish O
oil O
, O
could O
counteract O
some O
of O
the O
adverse O
effects O
induced O
by O
phthalates B
. O

Considerable O
amounts O
of O
ferulic B
, I
sinapinic I
and I
gallic I
acids I
, O
kaempferol B
, O
isorhamnetin B
and O
rutin B
were O
observed O
in O
the O
chemical O
ChL O
extract O
and O
were O
linked O
with O
its O
inhibitory O
effect O
on O
prostate O
cancer O
cell O
proliferation O
, O
motility O
and O
cellular O
competence O
for O
gap O
junctional O
communication O
. O

Exposure O
to O
2 B
, I
4 I
- I
dichlorophenoxyaceti I
acid I
alters O
glucose B
metabolism O
in O
immature O
rat O
Sertoli O
cells O
. O

Design O
, O
synthesis O
and O
biological O
activity O
of O
multifunctional O
alpha B
, I
beta I
- I
unsaturated I
carbonyl I
scaffolds O
for O
Alzheimer O
' O
s O
disease O
. O

A O
series O
of O
compounds O
containing O
an O
alpha B
, I
beta I
- I
unsaturated I
carbonyl I
moiety O
, O
such O
as O
chalcones B
and O
coumarins B
were O
designed O
, O
synthesized O
and O
tested O
in O
a O
variety O
of O
assays O
to O
assess O
their O
potential O
as O
anti O
- O
Alzheimer O
' O
s O
disease O
( O
AD O
) O
agents O
. O

We O
used O
bisulfite B
- O
PCR O
pyrosequencing O
to O
quantitate O
DNA O
methylation O
in O
long O
interspersed O
nuclear O
element O
- O
1 O
( O
LINE O
- O
1 O
) O
and O
O B
( I
6 I
) I
- I
methylguanine I
- O
DNA O
methyltransferase O
( O
MGMT O
) O
. O

Synthesis O
and O
Pharmacological O
Characterization O
of O
2 B
- I
( I
Acylamino I
) I
thiophene I
Derivatives O
as O
Metabolically O
Stable O
, O
Orally O
Effective O
, O
Positive O
Allosteric O
Modulators O
of O
the O
GABAB O
Receptor O
. O

Two O
recently O
reported O
hit O
compounds O
, O
COR627 B
and O
COR628 B
, O
underpinned O
the O
development O
of O
a O
series O
of O
2 B
- I
( I
acylamino I
) I
thiophene I
derivatives O
. O

In O
light O
of O
building O
chiral O
gamma B
- I
tertiary I
and I
quaternary I
carbon I
centers O
of O
butenolides B
, O
three O
synthetic O
strategies O
are O
included O
: O
1 O
) O
the O
reactions O
with O
furanone O
derivatives O
as O
nucleophiles O
, O
2 O
) O
olefination O
of O
gamma B
, I
gamma I
- I
disubstituted I
butenolides I
and O
3 O
) O
the O
reactions O
by O
using O
gamma B
, I
gamma I
- I
disubstituted I
butenolides I
as O
nucleophiles O
. O

In O
light O
of O
building O
chiral O
gamma B
- I
tertiary I
and I
quaternary I
carbon I
centers O
of O
butenolides B
, O
three O
synthetic O
strategies O
are O
included O
: O
1 O
) O
the O
reactions O
with O
furanone O
derivatives O
as O
nucleophiles O
, O
2 O
) O
olefination O
of O
gamma B
, I
gamma I
- I
disubstituted I
butenolides I
and O
3 O
) O
the O
reactions O
by O
using O
gamma B
, I
gamma I
- I
disubstituted I
butenolides I
as O
nucleophiles O
. O

In O
light O
of O
building O
chiral O
gamma B
- I
tertiary I
and I
quaternary I
carbon I
centers O
of O
butenolides B
, O
three O
synthetic O
strategies O
are O
included O
: O
1 O
) O
the O
reactions O
with O
furanone O
derivatives O
as O
nucleophiles O
, O
2 O
) O
olefination O
of O
gamma B
, I
gamma I
- I
disubstituted I
butenolides I
and O
3 O
) O
the O
reactions O
by O
using O
gamma B
, I
gamma I
- I
disubstituted I
butenolides I
as O
nucleophiles O
. O

In O
this O
mini O
review O
, O
we O
summarize O
our O
recent O
studies O
on O
transition B
metal I
- O
catalyzed O
green O
and O
atom O
efficient O
transformations O
of O
P B
( I
O I
) I
- I
H I
bonds O
to O
various O
versatile O
organophosphorus B
compounds O
, O
including O
the O
highly O
regio O
- O
and O
stereoselective O
P B
( I
O I
) I
- I
H I
additions O
to O
carbon B
- O
carbon B
unsaturated O
compounds O
, O
asymmetric O
hydrophosphorylation O
reactions O
, O
and O
dehydrogenative O
coupling O
reactions O
of O
P B
( I
O I
) I
- I
H I
compounds O
with O
carbon B
- O
H B
and O
heteroatom O
- O
H B
compounds O
. O

In O
this O
mini O
review O
, O
we O
summarize O
our O
recent O
studies O
on O
transition B
metal I
- O
catalyzed O
green O
and O
atom O
efficient O
transformations O
of O
P B
( I
O I
) I
- I
H I
bonds O
to O
various O
versatile O
organophosphorus B
compounds O
, O
including O
the O
highly O
regio O
- O
and O
stereoselective O
P B
( I
O I
) I
- I
H I
additions O
to O
carbon B
- O
carbon B
unsaturated O
compounds O
, O
asymmetric O
hydrophosphorylation O
reactions O
, O
and O
dehydrogenative O
coupling O
reactions O
of O
P B
( I
O I
) I
- I
H I
compounds O
with O
carbon B
- O
H B
and O
heteroatom O
- O
H B
compounds O
. O

In O
this O
mini O
review O
, O
we O
summarize O
our O
recent O
studies O
on O
transition B
metal I
- O
catalyzed O
green O
and O
atom O
efficient O
transformations O
of O
P B
( I
O I
) I
- I
H I
bonds O
to O
various O
versatile O
organophosphorus B
compounds O
, O
including O
the O
highly O
regio O
- O
and O
stereoselective O
P B
( I
O I
) I
- I
H I
additions O
to O
carbon B
- O
carbon B
unsaturated O
compounds O
, O
asymmetric O
hydrophosphorylation O
reactions O
, O
and O
dehydrogenative O
coupling O
reactions O
of O
P B
( I
O I
) I
- I
H I
compounds O
with O
carbon B
- O
H B
and O
heteroatom O
- O
H B
compounds O
. O

Indotertine B
B I
( O
2 O
) O
exists O
as O
a O
pair O
of O
rotamers O
about O
the O
N B
- I
C I
( I
O I
) I
bond O
with O
a O
2 O
: O
1 O
ratio O
and O
displays O
activities O
against O
HCT O
- O
8 O
and O
A549 O
tumor O
cell O
lines O
with O
IC50 O
values O
of O
6 O
. O
96 O
and O
4 O
. O
88 O
mu O
M O
, O
respectively O
. O

The O
objective O
of O
the O
current O
study O
was O
to O
determine O
whether O
a O
low O
- O
dose O
subchronic O
DEX B
treatment O
( O
100 O
mu O
g O
/ O
kg O
for O
8 O
consecutive O
days O
) O
exerts O
long O
- O
term O
effects O
on O
apoptosis O
in O
the O
adult O
rat O
prefrontal O
cortex O
( O
PFC O
) O
by O
examining O
the O
expression O
of O
cell O
death O
- O
promoting O
molecules O
( O
poly B
( I
ADP I
- I
ribose I
) I
polymerase O
( O
PARP O
) O
, O
p53 O
, O
procaspase O
3 O
, O
cleaved O
caspase O
3 O
, O
Bax O
) O
and O
cell O
- O
survival O
molecules O
( O
AKT O
, O
Bcl O
- O
2 O
) O
. O

The O
Glucuronidation O
of O
R B
- I
and I
S I
- I
Lorazepam I
: O
Human O
Liver O
Microsomal O
Kinetics O
, O
UDP B
- O
Glucuronosyltransfer O
Enzyme O
Selectivity O
, O
and O
Inhibition O
by O
Drugs O
. O

Respective O
mean O
Km O
and O
Vmax O
values O
for O
R B
- I
and I
S I
- I
lorazepam I
by O
HLM O
were O
29 O
+ O
/ O
- O
8 O
. O
9 O
and O
36 O
+ O
/ O
- O
10 O
mu O
M O
, O
and O
7 O
. O
4 O
+ O
/ O
- O
1 O
. O
9 O
and O
10 O
+ O
/ O
- O
3 O
. O
8 O
pmol O
/ O
min O
. O
mg O
. O

Microsomal O
intrinsic O
clearances O
were O
not O
significantly O
different O
, O
suggesting O
the O
in O
vivo O
clearances O
of O
R B
- I
and I
S I
- I
lorazepam I
are O
likely O
to O
be O
similar O
. O

Both O
R B
- I
and I
S I
- I
lorazepam I
were O
glucuronidated O
by O
UGT O
2B4 O
, O
2B7 O
, O
and O
2B15 O
, O
while O
R B
- I
lorazepam I
was O
additionally O
metabolized O
by O
the O
extra O
- O
hepatic O
enzymes O
UGT O
1A7 O
and O
1A10 O
. O

Based O
on O
in O
vitro O
clearances O
and O
consideration O
of O
available O
in O
vivo O
and O
in O
vitro O
data O
, O
UGT2B15 O
is O
likely O
to O
play O
an O
important O
role O
in O
the O
glucuronidation O
of O
R B
- I
and I
S I
- I
lorazepam I
. O

In O
order O
to O
identify O
potential O
drug O
- O
drug O
interactions O
, O
codeine B
, O
fluconazole B
, O
ketamine B
, O
ketoconazole B
, O
methadone B
, O
morphine B
, O
valproic B
acid I
, O
and O
zidovudine B
were O
screened O
as O
inhibitors O
of O
R B
- I
and I
S I
- I
lorazepam I
glucuronidation O
by O
HLM O
. O

The O
following O
surfactants O
were O
used O
in O
the O
experiments O
: O
cationic O
dodecyltrimethylammo B
bromide I
( O
DTAB B
) O
, O
anionic O
sodium B
dodecyl I
sulfate I
( O
SDS B
) O
, O
anionic O
Pantene O
shampoo O
which O
primarily O
contains O
sodium B
lauryl I
sulfate I
, O
nonionic O
tetraethylene B
glycol I
monooctyl I
ether I
( O
C8E4 B
) O
, O
and O
nonionic O
Pluronic B
( I
P I
- I
123 I
) I
surfactants O
at O
different O
concentrations O
. O

Storable O
sunshine O
, O
reusable O
rays O
: O
A O
solar O
rechargeable O
redox O
flow O
battery O
is O
proposed O
based O
on O
the O
photoregeneration O
of O
I3 B
( I
- I
) I
/ O
I B
( I
- I
) I
and O
[ B
Fe I
( I
C10 I
H15 I
) I
2 I
] I
( I
+ I
) I
/ O
Fe B
( I
C10 I
H15 I
) I
2 I
soluble O
redox O
couples O
, O
which O
can O
be O
regenerated O
by O
flowing O
from O
a O
discharged O
redox O
flow O
battery O
( O
RFB O
) O
into O
a O
dye O
- O
sensitized O
solar O
cell O
( O
DSSC O
) O
and O
then O
stored O
in O
tanks O
for O
subsequent O
RFB O
applications O
This O
technology O
enables O
effective O
solar O
- O
to O
- O
chemical O
energy O
conversion O
. O

A O
sensitive O
and O
selective O
imprinted O
solid O
phase O
extraction O
coupled O
to O
HPLC O
for O
simultaneous O
detection O
of O
trace O
quinoxaline B
- I
2 I
- I
carboxylic I
acid I
and O
methyl B
- I
3 I
- I
quinoxaline I
- I
2 I
- I
carboxylic I
acid I
in O
animal O
muscles O
. O

A O
new O
molecularly O
imprinted O
polymer O
( O
MIP O
) O
, O
selective O
for O
major O
metabolites O
of O
quinoxaline B
- I
1 I
, I
4 I
- I
dioxides I
, O
was O
prepared O
through O
bulk O
polymerisation O
using O
quinoxaline B
- I
2 I
- I
carboxylic I
acid I
( O
QCA B
) O
as O
template O
, O
diethylaminoethylmet B
as O
functional O
monomer O
and O
ethylene B
glycol I
dimethacrylate I
as O
cross O
- O
linker O
in O
tetrahydrofuran B
. O

Results O
showed O
that O
EEAP O
and O
quercetin B
but O
not O
ferulic B
acid I
protected O
beta O
- O
cells O
from O
glucotoxicity O
through O
several O
mechanisms O
, O
including O
: O
( O
1 O
) O
maintaining O
beta O
- O
cell O
viability O
; O
( O
2 O
) O
suppressing O
reactive O
oxygen B
species O
production O
; O
( O
3 O
) O
reducing O
characteristic O
features O
of O
apoptosis O
; O
( O
4 O
) O
inhibiting O
the O
activation O
of O
caspase O
- O
9 O
and O
caspase O
- O
3 O
and O
the O
cleavage O
of O
poly B
( I
ADP I
- I
ribose I
) I
polymerase O
; O
( O
5 O
) O
upregulating O
pancreatic O
and O
duodenal O
homeobox O
1 O
gene O
expression O
and O
the O

The O
12 O
flavonoids B
identified O
were O
quercetin B
3 I
- I
O I
- I
robinobioside I
, O
quercetin B
3 I
- I
O I
- I
rutinoside I
, O
quercetin B
3 I
' I
- I
O I
- I
galactoside I
, O
quercetin B
3 I
' I
- I
O I
- I
glucoside I
, O
quercetin B
3 I
' I
- I
O I
- I
rhamnoside I
, O
quercetin B
3 I
' I
- I
O I
- I
pentosylhexoside I
, O
quercetin B
3 I
- I
O I
- I
6 I
' I
malonylglucoside I
, O
quercetin B
3 I
' I
- I
O I
- I

The O
12 O
flavonoids B
identified O
were O
quercetin B
3 I
- I
O I
- I
robinobioside I
, O
quercetin B
3 I
- I
O I
- I
rutinoside I
, O
quercetin B
3 I
' I
- I
O I
- I
galactoside I
, O
quercetin B
3 I
' I
- I
O I
- I
glucoside I
, O
quercetin B
3 I
' I
- I
O I
- I
rhamnoside I
, O
quercetin B
3 I
' I
- I
O I
- I
pentosylhexoside I
, O
quercetin B
3 I
- I
O I
- I
6 I
' I
malonylglucoside I
, O
quercetin B
3 I
' I
- I
O I
- I

malonylglucoside I
, O
luteolin B
7 I
- I
O I
- I
6 I
' I
malonylglucoside I
, O
luteolin B
7 I
- I
O I
- I
malonylglucoside I
, O
myricetin B
3 I
- I
O I
- I
galactoside I
, O
and O
naringenin B
tri I
glycoside I
. O

malonylglucoside I
, O
luteolin B
7 I
- I
O I
- I
6 I
' I
malonylglucoside I
, O
luteolin B
7 I
- I
O I
- I
malonylglucoside I
, O
myricetin B
3 I
- I
O I
- I
galactoside I
, O
and O
naringenin B
tri I
glycoside I
. O

Biosynthesis O
of O
highly O
enriched O
( B
13 I
) I
C I
- I
lycopene I
for O
human O
metabolic O
studies O
using O
repeated O
batch O
tomato O
cell O
culturing O
with O
( B
13 I
) I
C I
- I
glucose I
. O

Biosynthesis O
of O
highly O
enriched O
( B
13 I
) I
C I
- I
lycopene I
for O
human O
metabolic O
studies O
using O
repeated O
batch O
tomato O
cell O
culturing O
with O
( B
13 I
) I
C I
- I
glucose I
. O

Advances O
in O
tomato O
cell O
culturing O
techniques O
offer O
an O
economical O
tool O
for O
generation O
of O
highly O
- O
enriched O
( B
13 I
) I
C I
- I
lycopene I
for O
human O
bioavailability O
and O
metabolism O
studies O
. O

To O
enhance O
the O
( B
13 I
) I
C I
- O
enrichment O
and O
yields O
of O
labelled O
lycopene B
from O
the O
hp O
- O
1 O
tomato O
cell O
line O
, O
cultures O
were O
first O
grown O
in O
( B
13 I
) I
C I
- I
glucose I
media O
for O
three O
serial O
batches O
and O
produced O
increasing O
proportions O
of O
uniformly O
labelled O
lycopene B
( O
14 O
. O
3 O
+ O
/ O
- O
1 O
. O
2 O
% O
, O
39 O
. O
6 O
+ O
/ O
- O
0 O
. O
5 O
% O
, O
and O
48 O
. O
9 O
+ O
/ O
- O
1 O
. O
5 O
% O
) O
with O
consistent O
yields O
( O
from O
5 O
. O
8 O
to O
9mg O
/ O
L O
) O
. O

An O
optimised O
9 O
- O
day O
- O
long O
( B
13 I
) I
C I
- O
loading O
and O
18 O
- O
day O
- O
long O
labelling O
strategy O
developed O
based O
on O
glucose B
utilisation O
and O
lycopene B
yields O
, O
yielded O
( B
13 I
) I
C I
- I
lycopene I
with O
93 O
% O
( B
13 I
) I
C I
isotopic O
purity O
, O
and O
55 O
% O
of O
isotopomers O
were O
uniformly O
labelled O
. O

In O
addition O
, O
gallic B
, I
vanilic I
and I
syringic I
acids I
, O
siringaldehyde B
, O
coniferaldehyde B
, O
sinapaldehyde B
, O
vanillin B
, O
5 B
- I
hydroxymethylfurfura I
and O
furfural B
were O
identified O
and O
quantified O
. O

Thiol B
derivatization O
of O
the O
alpha B
, I
beta I
- I
unsaturated I
amide I
present O
in O
most O
microcystins B
was O
recently O
shown O
to O
simplify O
analysis O
of O
LC O
- O
MS O
chromatograms O
of O
a O
Microcystis O
culture O
, O
making O
it O
easier O
to O
identify O
peaks O
corresponding O
to O
microcystins B
in O
complex O
mixtures O
. O

By O
changing O
to O
another O
polymer O
, O
poly B
( I
4 I
- I
vinylpyridine I
) I
/ O
graphene B
shows O
a O
stable O
and O
reversible O
response O
to O
pH O
, O
and O
demonstrates O
its O
potential O
for O
sensor O
application O
. O

6 B
- I
Dehydroshogaol I
( O
6 B
- I
DHSG I
) O
is O
a O
bioactive O
alpha B
, I
beta I
- I
unsaturated I
carbonyl I
compound O
isolated O
from O
fresh O
ginger O
with O
anti O
- O
inflammatory O
and O
phase O
II O
enzyme O
inducing O
activities O
. O

Together O
, O
these O
results O
indicate O
that O
GSH B
conjugation O
attenuates O
the O
biological O
activities O
of O
6 B
- I
DHSG I
and O
other O
alpha B
, I
beta I
- I
unsaturated I
carbonyl I
compounds O
. O

CLA O
treatment O
increased O
serum O
parathyroid O
hormone O
( O
PTH O
) O
significantly O
( O
p O
= O
0 O
. O
0172 O
) O
, O
while O
serum O
1 B
, I
25 I
- I
dihydroxyvitamin I
D3 I
concentration O
was O
not O
changed O
by O
CLA O
. O

Part O
6 O
: O
Indole B
- I
5 I
- I
cycloalkyl I
methylamines I
as O
selective O
serotonin B
reuptake O
inhibitors O
. O

These O
results O
together O
with O
overaccumulation O
of O
superoxide B
( O
O B
2 I
( I
* I
- I
) I
) O
and O
H2O2 B
in O
leaves O
revealed O
that O
Cu B
exposures O
induced O
oxidative O
stress O
. O

It O
was O
found O
that O
the O
ultrastable O
foam O
film O
obtained O
by O
the O
cooperation O
of O
magnesium B
ions O
and O
AE3S B
was O
driven O
from O
two O
aspects O
: O
one O
is O
the O
favorable O
arrangement O
of O
surfactant O
molecules O
, O
and O
the O
other O
is O
the O
increase O
of O
capacity O
of O
foam O
films O
for O
resolutely O
holding O
water O
molecules O
deduced O
by O
a O
dipolar O
pair O
formed O
by O
the O
flexible O
connecting O
head O
groups O
of O
AE3S B
and O
hydrated B
Mg I
( I
2 I
+ I
) I
via O
intermolecular O
coactions O
, O
both O
related O
to O
the O
presence O
of O
magnesium B
ions O
. O

Results O
of O
high O
- O
precision O
fitting O
of O
the O
second O
- O
harmonic O
EPR O
spectra O
of O
the O
small O
spin O
probe O
di B
- I
tert I
- I
butyl I
nitroxide I
( O
DTBN B
) O
in O
these O
aggregates O
together O
with O
viscosity O
, O
conductivity O
, O
and O
DLS O
showed O
that O
, O
at O
pH O
~ O
7 O
. O
54 O
, O
MTNa O
formed O
micelles O
and O
MPNa O
vesicles O
and O
MTNa O
exhibited O
a O
pH O
- O
induced O
micelle O
to O
vesicle O
transition O
as O
pH O
was O
lowered O
toward O
6 O
. O

The O
reaction O
kinetics O
between O
CO2 B
and O
trihexyl B
( I
tetradecyl I
) I
phosphonium I
( O
[ B
P66614 I
] I
) O
- O
based O
ionic O
liquids O
( O
ILs O
) O
with O
prolinate B
( O
[ B
Pro I
] I
) O
, O
2 B
- I
cyanopyrrolide I
( O
[ B
2 I
- I
CNpyr I
] I
) O
, O
and O
3 B
- I
( I
trifluoromethyl I
) I
pyrazolide I
( O
[ B
3 I
- I
CF3pyra I
] I
) O
anions O
are O
studied O
at O
temperatures O
from O
22 O
- O
60 O
degrees O
C O
. O

The O
results O
indicate O
partial O
first O
order O
reaction O
kinetics O
with O
respect O
to O
IL O
with O
values O
ranging O
from O
19 O
500 O
L O
mol O
( O
- O
1 O
) O
s O
( O
- O
1 O
) O
( O
[ B
P66614 I
] I
[ I
Pro I
] I
) O
to O
3200 O
L O
mol O
( O
- O
1 O
) O
s O
( O
- O
1 O
) O
( O
[ B
P66614 I
] I
[ I
3 I
- I
CF3pyra I
] I
) O
at O
22 O
degrees O
C O
. O

The O
second O
order O
reaction O
rate O
constants O
follow O
Arrhenius O
behavior O
with O
the O
highest O
activation O
energy O
of O
43 O
kJ O
mol O
( O
- O
1 O
) O
measured O
for O
[ B
P66614 I
] I
[ I
Pro I
] I
. O

One O
potential O
mechanism O
for O
its O
activity O
is O
the O
covalent O
modification O
of O
cellular O
proteins O
, O
via O
a O
reactive O
alpha B
, I
beta I
- I
unsaturated I
carbonyl I
group O
in O
its O
cyclopentenone B
ring O
, O
which O
in O
turn O
alters O
protein O
function O
. O

beta B
- I
estradiol I
17 I
- I
valerate I
affects O
embryonic O
development O
and O
sexual O
differentiation O
in O
Japanese O
medaka O
( O
Oryzias O
latipes O
) O
. O

beta B
- I
estradiol I
17 I
- I
valerate I
( O
EV O
) O
is O
a O
synthetic O
estrogen B
widely O
used O
in O
combination O
with O
other O
steroid B
hormones I
in O
hormone O
replacement O
therapy O
drugs O
and O
is O
detected O
in O
natural O
waters O
. O

Abstract O
This O
study O
investigates O
the O
solid O
- O
solid O
interactions O
between O
nimodipine B
( O
NIM B
) O
and O
polyethylene B
glycol I
( O
PEG B
) O
of O
different O
mean O
molecular O
weights O
( O
PEG B
2000 I
, I
4000 I
and I
6000 I
) O
, O
in O
solid O
dispersion O
systems O
, O
applying O
differential O
scanning O
calorimetry O
( O
DSC O
) O
, O
Fourier O
- O
Transform O
infrared O
spectroscopy O
, O
powder O
X O
- O
ray O
diffraction O
( O
PXRD O
) O
, O
hot O
stage O
microscopy O
( O
HSM O
) O
and O
theoretical O
modeling O
by O
the O
Flory O
- O
Huggins O
( O
FH O
) O
solution O
theory O
. O

Two O
new O
bis B
( I
trialkoxysilyl I
) I
derivatives O
of O
Gd B
( I
III I
) I
diethylenetriamine I
pentaacetate I
( O
Gd B
- I
DTPA I
) O
containing O
disulfide B
linkages O
are O
synthesized O
and O
used O
to O
form O
biodegradable O
Gd B
- I
PSQ I
particles O
by O
base O
- O
catalyzed O
condensation O
reactions O
in O
reverse O
microemulsions O
. O

Using O
cross O
- O
sectional O
scanning O
tunneling O
microscope O
( O
XSTM O
) O
with O
samples O
cleaved O
in O
situ O
in O
an O
ultrahigh O
vacuum O
( O
UHV O
) O
chamber O
, O
this O
study O
demonstrates O
the O
direct O
visualization O
of O
high O
- O
resolution O
interfacial O
band O
mapping O
images O
across O
the O
film O
thickness O
in O
an O
optimized O
bulk O
heterojunction O
polymer O
solar O
cell O
consisting O
of O
nanoscale O
phase O
segregated O
blends O
of O
poly B
( I
3 I
- I
hexylthiophene I
) I
( O
P3HT B
) O
and O
[ B
6 I
, I
6 I
] I
- I
phenyl I
C61 I
butyric I
acid I
methyl I
ester I
( O
PCBM B
) O
. O

Another O
purpose O
was O
to O
evaluate O
the O
effect O
of O
poly B
( I
L I
- I
lactide I
) I
( O
PLLA B
) O
or O
poly B
( I
D I
, I
L I
- I
lactide I
) I
( O
PDLLA B
) O
incorporation O
on O
crystallinity O
of O
pentablock O
copolymers O
and O
in O
vitro O
release O
profile O
of O
triamcinolone B
acetonide I
( O
selected O
as O
model O
drug O
) O
from O
nanoparticles O
. O

The O
OTMS B
- O
functionalized O
Au B
/ O
SiO2 B
core O
/ O
shell O
nanorods O
and O
nanospheres O
were O
then O
incorporated O
into O
the O
active O
layers O
of O
two O
OPV O
polymer O
systems O
: O
a O
poly B
( I
3 I
- I
hexylthiophene I
) I
: O
[ B
6 I
, I
6 I
] I
- I
phenyl I
- I
C61 I
- I
butyric I
acid I
methyl I
ester I
( O
P3HT B
: O
PCB60M B
) O
OPV O
device O
and O
a O
poly B
[ I
2 I
, I
6 I
- I
4 I
, I
8 I
- I
di I
( I
5 I
- I
ethylhexylthienyl I
) I
benzo I
[ I
1 I
, I
2 I
- I
b I
; I
3 I
, I
4 I

A O
dendritic O
family O
that O
fulfills O
these O
requirements O
is O
based O
on O
the O
2 B
, I
2 I
- I
bismethylolpropionic I
acid I
( O
bis B
- I
MPA I
) O
monomer O
. O

tert I
- I
butyl I
- I
2 I
- I
oxazoline I
) O
at O
room O
temperature O
and O
below O
, O
affording O
five O
- O
, O
six O
- O
, O
and O
seven O
- O
membered O
N B
- I
heterocyclic I
amines I
with O
enantiomeric O
excesses O
of O
> O
90 O
% O
in O
many O
cases O
and O
up O
to O
99 O
% O
. O

Statistically O
significant O
increases O
in O
the O
systemic O
exposure O
of O
ortho B
- I
and I
para I
- I
hydroxyatorvastatin I
were O
also O
observed O
upon O
concomitant O
dosing O
with O
CP B
- I
778 I
875 I
. O

Resonance O
attachment O
of O
low O
- O
energy O
electrons O
to O
xenobiotic O
molecules O
, O
2 B
, I
4 I
- I
dichlorophenoxyaceti I
acid I
( O
) O
, O
dichlorodiphenyltric B
( O
) O
and O
dichlorodiphenyldich B
( O
) O
, O
was O
investigated O
under O
gas O
- O
phase O
conditions O
by O
means O
of O
complementary O
experimental O
techniques O
. O

